Note: This story has been updated with comments from Roche's conference call to discuss its financial results.

注意：本故事已更新，包含罗氏在电话会议中讨论其财务业绩的评论。

NEW YORK – Impacts from China's

纽约——中国带来的影响

volume-based procurement program

基于数量的采购计划

and other healthcare pricing reforms led to flat Q1 diagnostics revenues year over year for Roche, company executives said Thursday.

罗氏公司高管周四表示，其他医疗定价改革导致罗氏第一季度诊断业务收入与去年持平。

Roche reported its diagnostics sales in the first quarter of 2025 came in

罗氏报告称其2025年第一季度的诊断业务销售额为

at CHF 3.49 billion ($4.23 billion).

约合34.9亿瑞士法郎（42.3亿美元）。

On a conference call to discuss the firm's Q1 financial results, Roche CEO Thomas Schinecker noted that the pricing reforms not only impacted Roche but also affected the entire diagnostics industry in China.

在讨论公司第一季度财务业绩的电话会议上，罗氏首席执行官托马斯·席内克指出，价格改革不仅影响了罗氏，还影响了整个中国诊断行业。

Roche Diagnostics CEO Matt Sause added that excluding China, diagnostic sales were up roughly 5 percent year over year. The firm saw a 15 percent revenue decline in the Asia-Pacific region that was heavily impacted by China, which is expected to continue throughout the year and will have a corresponding impact on profitability, he noted..

罗氏诊断首席执行官马特·索斯补充说，如果不包括中国，诊断业务的销售额同比增长了大约5%。他指出，受中国影响，亚太地区的收入下降了15%，这一趋势预计将持续全年，并对盈利能力产生相应影响。

Sales in China itself were down 23 percent, and Roche's team in China is implementing cost discipline measures to offset the impact of the government's pricing reforms. However, the company had a 'strong quarter' of instrument placements in China, and it remains a 'critical market for us,' Sause said.

罗氏公司在中国的销售额下降了23%，其在中国的团队正在实施成本控制措施，以抵消政府定价改革带来的影响。然而，索斯表示，公司在华设备投放取得了“强劲的季度表现”，中国仍然是一个“对我们至关重要的市场”。

.

。

Beyond China, Sause noted that instrument placements overall saw strong growth during the quarter. Core laboratory placements grew 65 percent, and molecular Cobas system placements were up 22 percent. Pathology lab instrument placements were up 10 percent, and digital pathology slide scanner placements were up 36 percent.

除了中国，Sause指出，本季度仪器的布局整体实现了强劲增长。核心实验室的布局增长了65%，分子Cobas系统布局增长了22%。病理实验室仪器布局增长了10%，数字病理切片扫描仪布局增长了36%。

The company's point-of-care Cobas Liat instrument saw placements increase 7 percent..

公司的床旁诊断仪器Cobas Liat的安装量增长了7%。

Core lab revenues,

核心实验室收入，

which comprised 55 percent of total diagnostics sales, were down 1 percent to CHF 1.90 billion from CHF 1.93 billion.

占总诊断销售额55%的业务，从19.3亿瑞士法郎下降了1%，至19亿瑞士法郎。

The core laboratory business was particularly affected by the reimbursement reductions and VBP program in China, offset partially by growth in the clinical chemistry business. Excluding China, the core lab business grew 8 percent.

核心实验室业务尤其受到中国报销额度减少和VBP项目的影响，部分被临床化学业务的增长所抵消。排除中国，核心实验室业务增长了8%。

Molecular lab

分子实验室

sales rose 4 percent to CHF 634 million from CHF 611 million in 2024 and contributed 18 percent of total diagnostics sales.

销售额从2024年的6.11亿瑞士法郎增长了4%，达到6.34亿瑞士法郎，占诊断业务总销售额的18%。

Sause noted that growth was spurred on by the blood screening segment, but the firm saw a 5 percent decline in the infectious disease business as HIV testing in Africa decreased as a result of paused USAID funding for testing. Excluding the HIV testing effect, molecular lab sales were up 6 percent.

Sause 指出，增长受到血液筛查领域的推动，但由于美国国际开发署（USAID）暂停了对检测的资助，导致非洲的艾滋病毒检测减少，公司的传染病业务下降了5%。排除艾滋病毒检测的影响，分子实验室销售额增长了6%。

Sales in the pathology lab segment grew 12 percent to CHF 417 million from CHF 372 million in 2024 and accounted for 12 percent of total diagnostics sales.

病理科实验室部门的销售额增长了12%，从2024年的3.72亿瑞士法郎增加到4.17亿瑞士法郎，占诊断业务总销售额的12%。

Roche's near-patient care business, which

罗氏的近患者护理业务， который

accounted for 15 percent of diagnostics sales, fell 6 percent to CHF 536 million from CHF 569 million

占诊断销售额的15%，从5.69亿瑞士法郎下降了6%至5.36亿瑞士法郎。

last year.

去年。

The decline was partially due to decreases in the blood glucose monitoring business as a result of the market shift to continuous glucose monitoring, Sause said. However, Roche is confident that its own continuous glucose monitoring solution and the launch of its Cobas Lumira point-of-care platform will drive growth for the near-patient care segment in the future, he added.

索斯表示，下降的部分原因是由于市场转向连续血糖监测，导致血糖监测业务减少。不过，罗氏有信心其自身的连续血糖监测解决方案以及Cobas Lumira床旁平台的推出将推动未来近患护理领域的增长，他补充道。

Roche does not anticipate a material contribution from continuous glucose monitoring in 2025 but is scaling up manufacturing..

罗氏预计2025年持续葡萄糖监测不会带来重大贡献，但正在扩大生产规模。

Sause noted that during Q1 the diagnostics division achieved two product launches of the planned 14 for the year. The company launched two Cobas Liat

索斯指出，在第一季度，诊断部门完成了全年计划14项产品发布中的两项。该公司推出了两款Cobas Liat产品。

sexually transmitted infection tests

性传播感染检测

and the

和

acute coronary syndrome diagnostic algorithm

急性冠脉综合征诊断算法

during the quarter.

在本季度期间。

Overall, Roche

总体而言，罗氏

posted CHF 15.44 billion in sales

销售额达154.4亿瑞士法郎

in the quarter

在这一季度

, up 7 percent

，上升了7个百分点

from CHF 14.40 billion in Q1 2024. At constant exchange rates, sales

从2024年第一季度的144亿瑞士法郎。按固定汇率计算，销售额

rose 6 percent year

玫瑰六年增百分之六

over year.

超过一年。

The pharmaceutical division

制药部门

had CHF 11.95 billion in Q1 sales

第一季度销售额为119.5亿瑞士法郎

,

，

up 9 percent

上涨9%

from CHF 10.92 billion in Q1 2024. At constant exchange rates

从2024年第一季度的109.2亿瑞士法郎。按固定汇率计算

, sales rose 8

，销售额增长了8

percent year over year.

百分比逐年。

Earlier this week, the company announced that it

本周早些时候，该公司宣布

intends to invest

打算投资

$50 billion

500亿美元

in the next five years into expanding its footprint in the US. The money will be used in part for a new research and development center that will act as a hub for the firm's cardiovascular, renal, and metabolism programs in Massachusetts.

在未来五年内扩展其在美国的业务。这笔资金将部分用于一个新的研发中心，该中心将成为该公司在马萨诸塞州的心血管、肾脏和代谢项目的核心基地。

Roche chose the Boston area because the firm 'didn't have [an R&D] presence on the East Coast,' Schinecker said.

施耐克表示，罗氏选择波士顿地区是因为该公司“在东海岸没有[研发]机构”。

The investment will also be used for a gene therapy manufacturing facility in Pennsylvania and expanded and upgraded manufacturing, distribution, and R&D sites in Kentucky, Indiana, New Jersey, Oregon, Arizona, and California for its medicines and diagnostics portfolio. Schinecker noted that the firm has been in negotiations with multiple different states for a new manufacturing site for peptides..

这笔投资还将用于宾夕法尼亚州的一家基因治疗制造工厂，以及扩建和升级肯塔基州、印第安纳州、新泽西州、俄勒冈州、亚利桑那州和加利福尼亚州的制造、分销和研发基地，以支持其药品和诊断产品组合。施内克指出，该公司一直在与多个不同的州就一个新的肽类制造基地进行谈判。

Schinecker said that it has always been Roche's strategy to build out its full value chain in the company's key markets, including the US, Europe, Japan, and China, to 'be present where the patients are.' The investment does not change the company's available capital expenditures and will not lead to a change in R&D spending, which is expected to remain flat in 2025.

施耐德表示，罗氏的战略一直是在其包括美国、欧洲、日本和中国在内的关键市场中构建完整的价值链，“在患者所在的地方提供服务”。这项投资不会改变公司的可用资本支出，也不会导致研发支出的变化，预计2025年研发支出将保持不变。

The firm will continue to remain 'disciplined when it comes to our spending,' he said..

他说道，公司在支出方面将继续保持“自律”。

Schinecker noted that the company has also put in mitigation measures to protect against

施内克指出，公司还采取了缓解措施以保护 against

the tariffs

关税

announced by President Donald Trump earlier this year. Roche does not expect much of an effect from tariffs in the first half of the year because it has shifted some inventories and increased manufacturing in the US and expects its measures 'should mitigate a significant impact already this year,' he said..

今年早些时候，唐纳德·特朗普总统宣布了这一消息。罗氏公司表示，不认为关税会在今年上半年产生多大影响，因为它已经转移了一部分库存，并增加了美国的生产制造。他还称，罗氏采取的措施“应该会减轻今年的重大影响”。

Roche confirmed its full-year outlook wit

罗氏确认了其全年展望。

h sales expected to increase in the mid-single-digit percent range at constant exchange rates

恒定汇率下，h销售预计将在中等个位数百分比范围内增长。

. The firm added that EPS for full-year 2025 is expected to

该公司补充说，预计2025年全年的每股收益（EPS）将

increase in the high-single-digit percent range.

高个位数百分比范围内的增长。